



**The Clatterbridge
Cancer Centre**
NHS Foundation Trust

Clatterbridge Road
Bebington
Wirral
CH63 4JY

Tel: 0151 556 5000
Web: www.clatterbridgecc.nhs.uk

Date: 17th November 2017

Re: Freedom of Information Request
Ref: 186-2017

Thank you for your email dated 25th October 2017 requesting information regarding Non-Small Cell Lung Cancer.

For the information requested please see Appendix 1.

Should you require any further information please do not hesitate to contact me on the email address provided below.

Please remember to quote the reference number above in any future communications.

If you are dissatisfied with the handling of your request, you have the right to ask for this to be investigated internally.

If you are dissatisfied with the information you have received, you have the right to ask for an internal review.

Both processes will be handled in accordance with our Trust's Freedom of Information Policy and the Freedom of Information Act 2000.

Internal investigation and internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to: Freedom of Information Review, The Clatterbridge Cancer Centre NHS Foundation Trust, Clatterbridge Road, Bebington, Wirral, CH63 4JY

If you are not satisfied with the outcome of the internal investigation/review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF.

In order for us to ensure customer satisfaction and to monitor compliance with the Freedom of Information Act 2000, we would be grateful if you could take a couple of minutes to complete a short feedback form via the link below:

<https://www.surveymonkey.co.uk/r/H39RFMM>

Appendix 1

FOI Request re Non-Small Cell Lung Cancer (NSCLC) Patients

How many of the following patients (excluding clinical trial patients) are currently being managed by your Health Trust:

Patient Type	Total number of patients (treated and not treated)	Number currently treated with any active anti-cancer drug treatment (excl. surgery/ radiotherapy only)	Number not treated (with any active anti-cancer drug treatment) NB – These patients may have received Radiotherapy or Surgery
All Non-Small Cell Lung Cancer (NSCLC) patients diagnosed between April-Sept 17	500	195	305
Patients with NSCLC Stage IIIB**/IV** (Stage 3b/4) (defined by using your criteria below)	248	126	122

Of the Stage IIIB/IV NSCLC patients, please state the number of patients currently being treated with the following therapies:

Therapy	Number of Stage IIIB/IV NSCLC patients currently treated
Afatinib (Giotrif)	10
Ceritinib (Zykadia)	1
Crizotinib (Xalkori)	2
Erlotinib (Tarceva)	0
Gefitinib (Iressa)	1
Nintedanib + docetaxel	0
Pemetrexed (Alimta) mono or in combination with carboplatin / cisplatin	18
Gemcitabine mono or in combination with carboplatin / cisplatin	27
Atezolizumab (Tecentriq)	0
Nivolumab (Opdivo)	0
Pembrolizumab (Keytruda)	28
Paclitaxel mono or in combination with carboplatin / cisplatin	0
Doxetaxel mono or in combination with carboplatin / cisplatin	0
Vinorelbine [or other Vinka alkaloid] mono or in combination with carboplatin / Cisplatin	38

If your trust does not treat Stage IIIB/IV NSCLC patients and you refer your patients to another trust, please state to which trust patients are referred

**TNM staging for Stage IIIB NSCLC = Any T, N3, M0 or T4, N2, M0

**TNM staging for Stage IV NSCLC = Any T, any N, M1